Accumulation of mutant p53V143A modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status

被引:23
作者
Bartussek, C [1 ]
Naumann, U [1 ]
Weller, M [1 ]
机构
[1] Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany
关键词
apoptosis; chemotherapy; glioma; p21(WAF1/CIP1); p53; radiotherapy;
D O I
10.1006/excr.1999.4654
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alterations of the p53 gene have been attributed a major role in the development and resistance to therapy of several human cancers. Accumulation of p53 in tumor cells may result from mutations associated with prolonged half-life or from stabilization of wild-type p53 by different mechanisms. To address the role of p53 accumulation in the response of malignant glioma cells to radiochemotherapy, we expressed the p53 mutant p53(V143A) in five human malignant glioma cell lines with different genetic and functional p53 status. Accumulation of p53(V143A) modulated proliferation ill three and clonogenicity in four of five cell lines without a clear pattern with regard to their endogenous p53 status. p53V143A inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell Lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A). Irradiation induced a moderate G2/M arrest in all cell lines, irrespective of the p53 status, that was unaffected by p53(V143A). Radiosensitivity as well as sensitivity to BCNU, teniposide (VM26), topotecan, vincristine, Taxol, and cisplatin both in cytotoxic cell death and in clonogenic cell death was unchanged in p53(V143A)-transfected cells with few exceptions. These data do not support the hypothesis that accumulation of mutant p53 is a major determinant of the response to adjuvant radiochemotherapy in human malignant glioma cells. (C) 1999 Academic Press.
引用
收藏
页码:432 / 439
页数:8
相关论文
共 42 条
[1]   DOMINANT-NEGATIVE P53 CAN RESTORE TUMORIGENICITY OF L-929 CELLS IN IMMUNOCOMPETENT MICE [J].
APPLEMAN, LJ ;
FREY, AB .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (04) :576-583
[2]   SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].
BAKER, SJ ;
MARKOWITZ, S ;
FEARON, ER ;
WILLSON, JKV ;
VOGELSTEIN, B .
SCIENCE, 1990, 249 (4971) :912-915
[3]   Loss of function and p53 protein stabilization [J].
Blagosklonny, MV .
ONCOGENE, 1997, 15 (16) :1889-1893
[4]   THE P53 GENE AND ITS ROLE IN HUMAN BRAIN-TUMORS [J].
BOGLER, O ;
HUANG, HJS ;
KLEIHUES, P ;
CAVENEE, WK .
GLIA, 1995, 15 (03) :308-327
[5]   GENETIC MECHANISMS OF TUMOR SUPPRESSION BY THE HUMAN P53 GENE [J].
CHEN, PL ;
CHEN, YM ;
BOOKSTEIN, R ;
LEE, WH .
SCIENCE, 1990, 250 (4987) :1576-1580
[6]   PROGNOSTIC IMPLICATIONS OF P53 OVEREXPRESSION IN SUPRATENTORIAL ASTROCYTIC TUMORS [J].
CHOZICK, BS ;
PEZZULLO, JC ;
EPSTEIN, MH ;
FINCH, PW .
NEUROSURGERY, 1994, 35 (05) :831-837
[7]   Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value [J].
Cunningham, JM ;
Kimmel, DW ;
Scheithauer, BW ;
OFallon, JR ;
Novotny, PJ ;
Jenkins, RB .
JOURNAL OF NEUROSURGERY, 1997, 86 (01) :121-130
[8]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[9]   PROGNOSTIC INDICATORS IN A RANGE OF ASTROCYTIC TUMORS - AN IMMUNOHISTOCHEMICAL STUDY WITH KI-67 AND P53 ANTIBODIES [J].
ELLISON, DW ;
STEART, PV ;
BATEMAN, AC ;
PICKERING, RM ;
PALMER, JD ;
WELLER, RO .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 59 (04) :413-419
[10]  
Friedlander P, 1996, MOL CELL BIOL, V16, P4961